A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer

Vaccine
Weihua YinJimin Gao

Abstract

A novel therapeutic vaccine against prostate cancer was developed by simultaneous immobilization of streptavidin-tagged bioactive GM-CSF and TNFalpha on the biotinylated surface of 30% ethanol-fixed RM-1 prostatic cancer cells. This study showed that the GM-CSF/TNFalpha-doubly surface-modified vaccine significantly extended the survival in the orthotopic model of RM-1 prostate cancer, and was superior to single GM-CSF- or TNFalpha-surface-modified vaccine. Moreover, the splenocytes from the GM-CSF/TNFalpha-vaccine-treated mice showed the most potent cytotoxicity on RM-1 cells and the highest production of RM-1-specific IFNgamma. In addition, more CD4+ and CD8+ T cells infiltrated into the tumor sites in the GM-CSF/TNFalpha-vaccine-treated mice than in the GM-CSF- or TNFalpha-vaccine-treated mice. Therefore, our study demonstrated that the efficacy of RM-1 prostate cancer cell vaccine could be improved by conjugating both GM-CSF and TNFalpha simultaneously on the surface of cancer cells, and that this modification thus has a potential translational significance.

References

Jun 1, 1994·The Journal of Experimental Medicine·E KämpgenG Schuler
Mar 19, 1997·Journal of the National Cancer Institute·M KawakitaT L Ratliff
Apr 26, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·M ChhikaraE Aguilar-Cordova
May 23, 2001·Critical Reviews in Oncology/hematology·E GalanisS J Russell
Apr 11, 2003·Proteomics·Mamoun AhramMichael R Emmert-Buck
Feb 19, 2004·Journal of the National Cancer Institute·John NemunaitisKristen Hege
Apr 29, 2004·Journal of Dermatological Science·Chikage ObataKunisuke Himeno
Aug 3, 2004·Nature Reviews. Immunology·Michael J Bevan
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Oct 27, 2004·Expert Opinion on Biological Therapy·Johannes Vieweg, Andrew Jackson
Oct 28, 2004·The Journal of Molecular Diagnostics : JMD·Mark A PerlmutterRodrigo F Chuaqui
Feb 3, 2005·Cancer Immunology, Immunotherapy : CII·Mark A SuckowMorris Pollard
Mar 1, 2005·Cytokine & Growth Factor Reviews·Simone MocellinDonato Nitti
May 23, 2006·Vaccine·Jimin GaoAkira Takashima
Sep 29, 2009·International Journal of Medical Microbiology : IJMM·Julia-Stefanie FrickIngo B Autenrieth

❮ Previous
Next ❯

Citations

Mar 5, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Maolei XuJingjing Liu
Aug 26, 2016·Human Vaccines & Immunotherapeutics·Ting-Wei YuJiantai Timothy Qiu
Dec 16, 2017·International Journal of Cancer. Journal International Du Cancer·Xiaojun ShiWanlong Tan
Jan 27, 2016·World Journal of Gastroenterology : WJG·Arvind GulbakeSanjay K Jain
May 28, 2016·Experimental Biology and Medicine·James Pk Armstrong, Adam W Perriman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.